While we did not detect differences in the subcellular localisation of calnexin by immunohistochemistry among good and poor responders, it is possible that the localisation of GRP78 and not its overall expression level or tumour/normal ratio determines its contribution to disease stage or clinical outcome of the patient. The gene discussed is HSPA5; the disease is neoplasm.